Press Releases by "Eisai Co., Ltd."

• Eisai and Quintiles Enter into a Strategic Collaboration to Develop Eisai’s Anticancer Compounds
  [ Pharmaceuticals | 2009-10-30]
• Eisai and Quintiles Enter into a Strategic Collaboration to Develop Eisai’s Anticancer Compounds
  [ Pharmaceuticals | 2009-10-30]
• GLOBAL PHASE III STUDY RESULTS SHOW ERIBULIN MEETS PRIMARY ENDPOINT OF OVERALL SURVIVAL
  [ Pharmaceuticals | 2009-10-30]
• Abbott Submits Marketing Authorization Application of Humira® (adalimumab), a Fully Human Monoclonal anti-TNF- Antibody, for the Treatment of Ankylosing Spondylitis in Japan
  [ Pharmaceuticals | 2009-10-28]
• Abbott Submits Marketing Authorization Application of Humira (adalimumab), a Fully Human Monoclonal anti-TNF- Antibody, for the Treatment of Ankylosing Spondylitis in Japan
  [ Pharmaceuticals | 2009-10-28]
• Eisai and TSD Japan Enter into a License and Joint Development Agreement of Denileukin Diftitox in Japan
  [ Pharmaceuticals | 2009-10-26]
• Eisai Launches “Crystal Veil”- an Allergen Screen Topical Gel
  [ Pharmaceuticals | 2009-10-19]
• Eisai Launches “Crystal Veil”- an Allergen Screen Topical Gel
  [ Pharmaceuticals | 2009-10-19]
• Eisai Opens Regional Office in Bahrain
  [ Pharmaceuticals | 2009-10-16]
• Application Submitted for Additional Indications for Helicobacter pylori Eradication by Concomitant Therapy with Proton Pump Inhibitors
  [ Pharmaceuticals | 2009-10-01]
• Abbott and Eisai Submit Application for Approval of Humira® (Adalimumab), a Fully Human Monoclonal Anti-TNF- Antibody, for the Treatment of Crohn's Disease in Japan
  [ Pharmaceuticals | 2009-09-30]
• Abbott and Eisai Submit Application for Approval of Humira (Adalimumab), a Fully Human Monoclonal Anti-TNF- Antibody, for the Treatment of Crohn's Disease in Japan
  [ Pharmaceuticals | 2009-09-30]
• KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos® Tablets in China, India, Sri Lanka and ASEAN Countries
  [ Pharmaceuticals | 2009-09-29]
• Eisai and DNDi  Enter into a Collaboration and License Agreement to Develop a New Drug for Chagas Disease
  [ Pharmaceuticals | 2009-09-29]
• Eisai Submits Application for Additional Indication of its Proton Pump Inhibitor PARIET® for Non-erosive GERD in Japan
  [ Pharmaceuticals | 2009-09-29]
• Eisai Submits Application for Additional Indication of its Proton Pump Inhibitor PARIET for Non-erosive GERD in Japan
  [ Pharmaceuticals | 2009-09-29]
• KYORIN and Eisai Sign License Agreement for Development and Marketing of Uritos Tablets in China, India, Sri Lanka and ASEAN Countries
  [ Pharmaceuticals | 2009-09-29]
• Eisai and DNDi Enter into a Collaboration and License Agreement to Develop a New Drug for Chagas Disease
  [ Pharmaceuticals | 2009-09-29]
• Eisai Announces Agreement with Pfizer on Strategic Alliance for Alzheimer's Disease Treatment Aricept®
  [ Pharmaceuticals | 2009-09-25]
• Eisai Announces Agreement with Pfizer on Strategic Alliance for Alzheimer's Disease Treatment Aricept
  [ Pharmaceuticals | 2009-09-25]

Most Popular: "Eisai Co., Ltd."